Targets › CDK4
46 programs from 37 companies in 264 trials: 138 Phase 2, 71 Phase 1, 49 Phase 3, 6 Phase 4; Oncology, Other, Gastroenterology; next expected readout Nov 2026.
Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1)…. (UniProt, P11802)
Open in Phaseline: the race on CDK4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Ribociclib (LEE011) Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor | CDK4, CDK6 | Phase 4 | Metastatic Breast Cancer; Early Breast Cancer; Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies; Breast Cancer … | Dec 2026 |
| Ottawa Hospital Research Institute | CDK4/6 inhibitor Cyclin-dependent kinase 4/6 inhibitor | CDK4, CDK6 | Phase 4 | Metastatic Breast Cancer | Mar 2027 |
| Pharmacosmos | Trilaciclib Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor | CDK4, CDK6 | Phase 4 | Extensive-stage Small-cell Lung Cancer; Limited Stage Small Cell Lung Cancer; Osteosarcoma; Head and Neck Cancer Squamous Cell Carcinoma … | Oct 2027 |
| Eli Lilly | Abemaciclib (LY2835219) Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor | CDK4, CDK6 | Phase 3 | Non Small Cell Lung Cancer; Breast Cancer; Breast Neoplasms; Prostatic Neoplasms … | Nov 2026 |
| BeOne Medicines | BGB-43395 Cyclin-dependent kinase 4 inhibitor | CDK4 | Phase 3 | HR+/HER2- Breast Cancer; Healthy Adult Participants; Hormone-receptor-positive Breast Cancer; Advanced Solid Tumor | Nov 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQB3616 capsule CDK2/4/6 inhibitor | CDK2, CDK4, CDK6 | Phase 3 | HR-positive, HER2-negative Breast Neoplasms; Breast Cancer; Metastatic Breast Cancer | Dec 2026 |
| Pfizer | Palbociclib CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor | CCND1, CDK6, CDK4 | Phase 3 | Breast Cancer; Ewing Sarcoma; Breast Cancer Recurrent; Metastatic Breast Cancer … | Dec 2026 |
| Shandong Suncadia Medicine | HRS-8080 CDK4/6 inhibitor | CDK4, CDK6 | Phase 3 | Locally Advanced Breast Cancer; Locally Advanced or Metastatic Breast Cancer; Breast Cancer; Unresectable or Metastatic Breast Cancer … | Dec 2026 |
| Fudan University | Dalpiciclib (SHR6390) CDK4/6 inhibitor | CDK4, CDK6 | Phase 3 | Advanced Breast Cancer; Breast Cancer | Feb 2027 |
| Pfizer | PF-07220060 CDK4 inhibitor | CDK4 | Phase 3 | Breast Cancer; Advanced or Metastatic Breast Cancer; Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Liposarcoma | Feb 2027 |
| Fudan University | Dalpiciclib (SHR-6390) Cyclin-dependent kinase 4/6 inhibitor | CDK4, CDK6 | Phase 3 | Breast Cancer; Breast Cancer Metastatic; Breast Neoplasm | Jun 2027 |
| Jiangsu Simcere Pharmaceutical | Trilaciclib Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor | CDK4, CDK6 | Phase 3 | Myelosuppression | Jul 2027 |
| Tokyo Medical and Dental University | CDK4/6 inhibitor CDK4/6 inhibitor combined with hormonal therapy (aromatase inhibitor or fulvestrant) with | CDK4, CDK6 | Phase 3 | Breast Cancer | Nov 2029 |
| Fudan University | Dalpicilib CDK4/6 inhibitor | CDK4, CDK6 | Phase 3 | Breast Cancer | Sep 2030 |
| Jiangsu HengRui Medicine | SHR6390 CDK4/6 inhibitor | CDK4, CDK6 | Phase 3 | Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast Cancer | Oct 2031 |
| Fujian Cancer Hospital | dalpiciclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 3 | Breast Cancer; Breast Diseases | Dec 2031 |
| SWOG Cancer Research Network | Cyclin-Dependent Kinase 4/6 Inhibitor CDK4/6 inhibitor | CDK4, CDK6 | Phase 3 | Anatomic Stage IV Breast Cancer AJCC v8 | May 2032 |
| Hebei Medical University Fourth Hospital | Dalpiciclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Breast Cancer | Dec 2026 |
| Shengjing Hospital | SHR6390 CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Breast Cancer | Dec 2026 |
| Tianjin Medical University Cancer Institute and Hospital | Dalpiciclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | CANCER; Non-small Cell Lung Cancer | Dec 2026 |
| Sun Yat-sen University | Dalpiciclib Isetionate Tablets CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Hepatocellulcar Carcinoma; Advanced/Metastatic Breast Cancer | Dec 2026 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | CDK4/6 inhibitor CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Breast Cancer | Aug 2027 |
| Peking University | Dalpiciclib Isethionate CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Esophageal Squamous Cell Carcinoma | Oct 2027 |
| Washington University School of Medicine | PD0332991 CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Breast Neoplasms | Nov 2027 |
| Shengjing Hospital | Dalpiciclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Breast Cancer | Dec 2027 |
| University of California, San Diego | A CDK4/6 inhibitor different from the first that the participant had received, p CDK4/6 inhibitor plus fulvestrant (selective estrogen receptor degrader) | CDK4, CDK6 | Phase 2 | Breast Cancer | Dec 2027 |
| AstraZeneca | Atirmociclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Advanced Breast Cancer | Dec 2027 |
| Canadian Cancer Trials Group | RP-6306 (Lunresertib) CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Breast Cancer | Dec 2027 |
| Zhejiang Cancer Hospital | dalpiciclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Breast Cancer | Dec 2027 |
| Henan Cancer Hospital | Dalpiciclib Isethionate Tablets CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Breast Neoplasms | Jan 2028 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Culmerciclib CDK2/4/6 inhibitor | CDK2, CDK4, CDK6 | Phase 2 | HR+/HER2- Early Breast Cancer | May 2028 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Fovinaciclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | HR+/HER2+ Early Breast Cancer | May 2028 |
| Fudan University | Culmerciclib CDK2/4/6 inhibitor | CDK2, CDK4, CDK6 | Phase 2 | Breast Cancer | Jun 2028 |
| The First Affiliated Hospital with Nanjing Medical University | Culmerciclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Breast Cancer | Aug 2028 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Culmerciclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Hormone Receptor-Positive Breast Cancer | Sep 2028 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | dalpiciclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Salivary Gland Carcinoma | Oct 2028 |
| Sun Yat-sen University | Culmerciclib CDK2/4/6 inhibitor | CDK2, CDK4, CDK6 | Phase 2 | Breast Cancer | Dec 2028 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Dalpicilib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Dec 2028 |
| Peking University People's Hospital | Dalpiciclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Hormone Receptor-Positive Breast Cancer | Dec 2029 |
| UNC Lineberger Comprehensive Cancer Center | Selective Estrogen Receptor Degrader (SERD) CDK4/6 inhibitor | CDK4, CDK6 | Phase 2 | Breast Cancer | Jun 2031 |
| Shanghai Hengrui Pharmaceutical | SHR6390 CDK4/6 inhibitor | CDK4, CDK6 | Phase 1 | ER-Positive, HER2-Negative Breast Cancer | Dec 2026 |
| Tasly Pharmaceuticals | TSL2109 CDK4/6-DYRK2 dual-target inhibitor | CDK4, CDK6, DYRK2 | Phase 1 | Metastatic Castration-Resistant Prostate Cancer Patients | Dec 2026 |
| University of Washington | Samuraciclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 1 | Resectable Pancreatic Ductal Adenocarcinoma | Jul 2027 |
| NiKang Therapeutics | NKT5097 CDK2/CDK4 dual degrader | CDK2, CDK4 | Phase 1 | HR+ Breast Cancer | Jul 2027 |
| Pfizer | Atirmociclib CDK4/6 inhibitor | CDK4, CDK6 | Phase 1 | Hepatic Impairment | Aug 2027 |
| Avenzo Therapeutics | AVZO-023 CDK4 inhibitor | CDK4 | Phase 1 | HR+/HER2- Breast Cancer | Aug 2028 |
Breast Cancer (62) Metastatic Breast Cancer (13) Breast Neoplasms (8) HR+/HER2- Breast Cancer (5) Advanced Breast Cancer (5) Endometrial Cancer (4) Early Breast Cancer (3) Breast Cancer Female (3) Estrogen-receptor-positive Breast Cancer (3) Anatomic Stage IV Breast Cancer AJCC v8 (3) Advanced Dedifferentiated Liposarcoma (3) Anatomic Stage II Breast Cancer AJCC v8 (2)
small molecule (30), mixed (12), antibody (1), other (1), protein or peptide (1)
Fudan University (4) Pfizer (3) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (2) Shengjing Hospital (2) Sun Yat-sen University (2) Novartis (1) Pharmacosmos (1) Fujian Cancer Hospital (1) Peking University (1) BeOne Medicines (1) SWOG Cancer Research Network (1) Eli Lilly (1) Jiangsu HengRui Medicine (1) Avenzo Therapeutics (1) Shandong Suncadia Medicine (1) Chia Tai Tianqing Pharmaceutical Group (1) Tasly Pharmaceuticals (1) Hebei Medical University Fourth Hospital (1) Jiangsu Simcere Pharmaceutical (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.